Table 2

Survival and time to progression according to biological markers

Median survivalMedian time to progression
Mo95% CIaPMo95% CIP
Gemcitabine plus cisplatin
RRM1
  ≤1.413.79.6–17.80.0098.45.4–11.30.020
  >1.43.60–8.12.72.5–2.9
ERCC1
  ≤1.713.70.3–270.1908.44.5–12.20.070
  >1.79.56.3–12.85.11–9.3
RRM1 and ERCC1
  ≤1.4 and ≤1.7NR0.020114.2–17.80.030
  >1.4 and >1.76.82.6–11.12.72.6–2.9
 Others8.30–21.75.13.3–6.9
Gemcitabine plus cisplatin plus vinorelbine
RRM1
  ≤1.411.14.9–17.30.8207.14.3–9.90.890
  >1.4110–24.77.10–16.2
ERCC1
  ≤1.710.63–18.20.8707.13.1–11.10.830
  >1.7116.7–15.27.10.9–13.4
RRM1 and ERCC1
  ≤1.4 and ≤1.711.13.4–18.70.2907.13.4–10.80.630
  >1.4 and >1.718.93.3–34.510.81.4–20.1
 Others3.20–12.82.20–8.8
Gemcitabine plus vinorelbine followed by vinorelbine plus ifosfamide
RRM1
  ≤1.48.84.9–12.70.78064.3–7.70.760
  >1.46.93.9–9.95.13.8–6.3
ERCC1
  ≤1.76.92.5–11.30.5305.53.9–70.840
  >1.77.50–15.95.12.8–7.4
RRM1 and ERCC1
  ≤1.4 and ≤1.78.84.3–13.30.7405.53.6–7.40.090
  >1.4 and >1.75.90.9–144.60–9
 Others7.55–6.79.90–20.4
  • a CI, confidence interval; NR, not reached; RRM1, ribonucleotide reductase subunit M1; ERCC1, excision repair cross-complementary group 1.